Shares of MyWant Sciences rose 27 percent on Monday when its parent Sumitovant Biopharma unveiled an agreement with Pfizer Inc. to jointly pay અને 4.2 billion for prostate cancer and women’s health. Mewant Mayov, + 20.48% rel and ૦ 0 million of payment will be received, and Market Regulix, a …
Read More »Mayovant’s stock rises 27% on news of Pfizer prostate cancer drug collaboration up to 2 4.2 billion
